骁悉(MMF)预防肾移植术后急性排斥的临床观察

应用新型免疫抑制剂MMF预防肾移植术后急性排斥进行随机对照临床观察。MMF应用组11例,对照组10例。随访十二个月以上,排斥均有病理证实。结果提示;MMF组发生急性排斥仅占9％(1/11),经小剂量激素冲击逆转。对照组发生急性排斥占30％(3/10),2例为难治性排斥,经大剂量激素、OKT_3治疗无效后改用MMF,急性排斥逆转,肾功能恢复正常,1例细胞性排斥经大剂量激素冲击治愈。对照组1例肝胰损害患者改用MMF后治愈。临床研究表明MMF具有预防和减少急性排斥发生的效果而且有抗难治性排斥的作用,还具有对CsA有严重并发症者的补救作用,MMF的安全性稳定。副作用主要是腹泻,减药可缓解。

A Clinical Study of MMF in Preventing Acute Renal Allograft Rejection

The new immunosuppressant MMF, which prevents acute rejection alter renal trnasplanta-tion, has been evaluated by a randomized controlled study. Eleven cases were treated with MMF and ten others were well controlled. All rejection cases were confirmed by pathology. 12 months follow-up were undertaken. Only one case (9%) developed acute rejection in MMF group and converted after low dose MP, Three cases (30%) developed acute rejection in controlled group, 2 refractory rejection, which were treated with MMF because of non-efficiency with high dose MP and OKT3, were converted and renal function recovered. 1 cellular rejection was cured after high dose MP in controlled group. 1 case converse to MMF because of liver and pancreas damage. The result showed MMF can prevent reduce acute rejection and treat refractory rejection. MMF has rescue effect on severe complication with CsA. MMF is saft and Diarrhea is the major ad- verse event, which can be relieved after dose.